The Supreme Court Just Ruled Against Roundup Cancer Victims — Here Is What It Means for You
You may have heard the news on June 25, 2026, and felt the floor drop out from under you. The Supreme Court ruled 7-2 to side with Bayer, the manufacturer of Roundup, overturning a Missouri jury’s verdict for a man who spent more than two decades spraying the weedkiller before a doctor told him he had non-Hodgkin’s lymphoma. The ruling is expected to block thousands of similar lawsuits across the country — cases filed by farmers, landscapers, groundskeepers, and homeowners who did the same thing that plaintiff did: they used Roundup, year after year, and then got a cancer diagnosis they never saw coming.
If that is your story — or your father’s, your mother’s, your spouse’s — you need to hear the truth, and you need it now, before frustration becomes surrender. The science connecting glyphosate to cancer has not changed. The International Agency for Research on Cancer still classifies it as a probable human carcinogen. What changed is the legal door. And a narrowed door is not always a closed one.
We are Attorney911 — The Manginello Law Firm. We handle toxic tort and product liability cases, and what we owe you here is not optimism but honesty: what the ruling did, what it did not do, which legal theories may still survive, and exactly what evidence you need to preserve before it disappears. We are not going to tell you your case is easy. It is not. We are going to tell you what is true, what is possible, and what to do about it.
What the 7-2 Decision Actually Does (and What It Does Not Do)
The Supreme Court’s ruling overturns a Missouri jury verdict for a plaintiff who claimed more than twenty years of Roundup exposure caused his non-Hodgkin’s lymphoma — a cancer of the lymphatic system that attacks the body’s white blood cells. The decision is expected to block thousands of similar lawsuits across the country. Here is what that means in plain language.
The federal law that governs pesticide labels — the Federal Insecticide, Fungicide, and Rodenticide Act, known as FIFRA — requires the EPA to review and approve every pesticide label before the product can be sold. The EPA has consistently maintained that glyphosate, the active ingredient in Roundup, is “not likely to be carcinogenic to humans” when used according to the label directions. Because the EPA did not require a cancer warning on Roundup’s label, the Supreme Court held that state courts cannot impose a different labeling requirement through tort law. In other words, a Missouri jury cannot order Bayer to put a cancer warning on its product when the federal agency that regulates pesticides specifically decided no such warning was needed.
That is the core of the preemption ruling, and it is a serious blow. The failure-to-warn theory — the argument that Monsanto and Bayer should have warned users that Roundup could cause cancer — was the backbone of the Roundup litigation. It was the theory that produced the Missouri jury verdict the Supreme Court just overturned. It was the theory behind thousands of pending claims in the federal Multi-District Litigation consolidated in the Northern District of California, where approximately 3,900 actions were pending as of June 2026.
But here is what the ruling does not do. It does not rewrite the science. The IARC classification stands. It does not prohibit every legal theory against the manufacturer — it targets state-law failure-to-warn claims premised on labeling requirements that conflict with the EPA’s federal labeling determination. The ruling does not erase the retraction of the Williams et al. paper — a foundational safety study the EPA relied upon — for ethical concerns and research misconduct. And it does not prevent a qualified attorney from evaluating whether your specific facts fit a theory that survives the preemption analysis.
The honest assessment is this: the ruling forecloses the most common and most powerful legal theory, which means the path to compensation is significantly harder and narrower than it was before June 25, 2026. But “harder” is not “impossible,” and “narrower” is not “closed.” The question that matters now is whether your case fits through one of the remaining doors — and that question requires a theory-specific preemption analysis by an attorney who understands both FIFRA and the surviving tort theories.
“The U.S. Supreme Court decision is good for science, farmers, and industries that depend on regulatory clarity for innovation. It should help significantly contain the Roundup litigation after nearly a decade of legal battles.”
That is Bayer’s own statement after the ruling. Read it carefully. Bayer says the decision should “help significantly contain” the litigation — not end it. Even the manufacturer acknowledges the litigation continues. The question is what form it takes now, and which plaintiffs still have a viable path.
The Science Has Not Changed — Only the Legal Door Has Narrowed
The International Agency for Research on Cancer — the World Health Organization’s specialized cancer agency — classified glyphosate as a “probable human carcinogen” in 2015. That classification was based on published, peer-reviewed literature, animal toxicology studies, epidemiological studies of exposed workers, and mechanistic evidence. It was not a lawyer’s argument. It was the conclusion of an independent panel of scientists who reviewed the body of evidence and determined that glyphosate probably causes cancer in humans — specifically non-Hodgkin’s lymphoma.
The EPA disagrees. The EPA has maintained that glyphosate is “not likely to be carcinogenic to humans” when used according to label directions. This is the position Bayer relies on, and it is the position the Supreme Court deferred to in its preemption ruling. But here is the part that matters: the EPA’s determination was based, in significant part, on data supplied by the manufacturer itself — and one of the key studies the EPA relied upon has been retracted.
Think about that for a moment. The federal agency that said glyphosate is safe was leaning on a paper that the scientific community later pulled from the record because of research misconduct. The regulatory determination the Supreme Court just elevated above state tort law was built, in part, on compromised science. That fact does not change the legal ruling — the Supreme Court held that the EPA’s labeling determination preempts state warning requirements regardless. But it does mean the underlying scientific debate is far from settled, and it opens the door to legal theories that attack the manufacturer’s own conduct rather than the label itself.
One oncologist who served as an expert witness in the first Roundup trials drew a parallel that is worth sitting with. Sixty years ago, the medical profession thought tobacco was safe. Doctors appeared in advertisements endorsing cigarettes. People smoked in hospitals. The science evolved, and what everyone “knew” turned out to be wrong — not because the truth changed, but because the evidence finally overcame the industry narrative. Glyphosate may or may not follow the same trajectory. But the IARC classification, the retracted safety study, and the ongoing scientific debate all point to the same conclusion: the question of whether Roundup causes cancer is not closed. Only one legal theory has been narrowed.
The Retracted Study: How Litigation Uncovered What the EPA Relied On
This is the fact that should anger you most, and it is the fact that may keep some cases alive.
A key scientific paper — authored by Williams and colleagues — was one of the foundational studies the EPA relied upon when it determined that glyphosate is not likely to be carcinogenic. For years, this paper has been cited by the manufacturer and by industry advocates as proof that Roundup is safe. And it was retracted.
The retraction came because of ethical concerns and research misconduct. Not because the science evolved naturally. Not because new data superseded old conclusions. Because the integrity of the research itself was called into question — and the questions were surfaced through litigation discovery, through the lawsuits that forced internal documents into the light, through the courtroom process that the Supreme Court has now partially foreclosed.
This matters for two reasons. First, it means the regulatory record the Supreme Court deferred to — the EPA’s determination that no cancer warning was needed — was built on a foundation that includes a retracted, ethically compromised study. The EPA’s position may still be legally controlling for preemption purposes, but its scientific credibility is damaged. Second, and more important for your case: the retraction supports legal theories that go beyond the label. If the manufacturer knew its safety data was compromised and presented it to the EPA anyway, or if it concealed the problems from regulators and the public, that is not a failure-to-warn claim — that is a fraud claim, a concealment claim, a negligent-testing claim. And those theories may not be preempted by FIFRA’s labeling provisions.
The distinction is critical. The Supreme Court’s ruling appears to preempt claims that demand a different or additional warning on the product label. But a claim that the manufacturer defrauded the EPA — that it submitted compromised research and concealed the problems — targets the manufacturer’s own conduct, not the adequacy of the label. Whether such claims survive preemption is the question that will occupy courts for months, perhaps years, after this ruling. And it is the question a qualified attorney must answer before recommending whether your case is worth pursuing.
Non-Hodgkin’s Lymphoma: The Cancer at the Center of Every Roundup Case
Non-Hodgkin’s lymphoma is a cancer that begins in the lymphatic system — the body’s network of lymph nodes, spleen, thymus, and bone marrow that produces and circulates white blood cells called lymphocytes. When lymphocytes become abnormal, they multiply uncontrollably, crowding out healthy cells and impairing the body’s ability to fight infection. NHL is not one disease but a group of more than seventy subtypes, each with its own behavior, prognosis, and treatment protocol.
The symptoms often arrive quietly. A swelling in the neck, armpit, or groin that does not go away. Persistent fatigue. Unexplained weight loss. Night sweats that soak the sheets. Fever without an obvious cause. Many patients first notice a lump while shaving or showering and dismiss it as a harmless node. By the time a biopsy confirms the diagnosis, the cancer may already be widespread through the lymphatic system.
Diagnosis requires a lymph node biopsy — the surgical removal of tissue for microscopic examination by a pathologist who identifies the specific subtype. Additional testing includes blood work, CT scans, PET scans, and sometimes bone marrow biopsy to determine how far the disease has spread. The subtype and stage dictate everything that follows.
Treatment depends on the subtype and aggressiveness. For many patients, the first line is chemotherapy — drug combinations designed to kill cancer cells throughout the body. A common regimen called R-CHOP combines five drugs administered in cycles over several months. Immunotherapy — targeted antibodies like rituximab that train the immune system to attack cancer cells — has become standard for many subtypes. Radiation therapy may be used for localized disease. For aggressive or relapsed cases, a stem cell transplant may be necessary, which involves high-dose chemotherapy to destroy the bone marrow followed by infusion of healthy stem cells to rebuild the blood-producing system.
The cost is staggering. A single course of chemotherapy can run tens of thousands of dollars. Immunotherapy drugs can cost thousands per dose. A stem cell transplant can exceed hundreds of thousands of dollars. And the surveillance does not end when treatment does — patients undergo regular scans and blood work for years, sometimes for life, watching for recurrence. For agricultural workers whose physical labor capacity may be permanently diminished by treatment, the lost earning capacity compounds the medical burden.
For families who have lost a loved one to NHL, the wrongful death claim carries its own legal framework — one that may provide a separate path if the underlying liability theory survives preemption. Missouri’s wrongful death statute allows certain family members to recover for the loss of their loved one’s financial support, companionship, and guidance. But the survival of any wrongful death claim still depends on whether a viable underlying theory of liability exists after the Supreme Court’s ruling.
The connection between glyphosate and NHL is the scientific foundation of every Roundup case. The IARC based its 2015 classification on epidemiological studies showing elevated NHL rates among workers with heavy glyphosate exposure, animal studies showing tumor formation, and mechanistic evidence suggesting how glyphosate could damage cells. The defense counters with the EPA’s contrary position, the retracted Williams paper, and the absence of a scientific consensus. In court, this battle is fought through expert witnesses — oncologists, toxicologists, epidemiologists — who present and defend the science under cross-examination. After the Supreme Court’s preemption ruling, the science matters most for claims that survive on non-warning theories, where general causation remains the battlefield.
Which Legal Theories May Still Survive the Preemption Ruling
This is the section that matters most, and we are going to be honest about every word of it.
The Supreme Court’s 7-2 ruling appears to preempt state-law failure-to-warn claims — the theory that Monsanto and Bayer should have warned users that Roundup could cause cancer. That theory required the manufacturer to add a cancer warning to the product label, and the Court held that FIFRA’s labeling provisions prevent states from imposing warning requirements different from what the EPA approved. This is the theory that produced the Missouri jury verdict the Court overturned. It is the theory behind most of the pending Roundup cases. And it is likely no longer available as a standalone claim.
But the law of product liability is not a single theory. It is a set of distinct claims, each with its own elements, its own proof requirements, and its own relationship to federal preemption. Here are the theories that may survive — and the honest uncertainty that accompanies each one.
Design defect. A design defect claim argues that the product itself — its formulation, its active ingredient — is unreasonably dangerous regardless of what the label says. This theory does not demand a different warning. It challenges the decision to put glyphosate on the market at all, or at the concentrations used, when safer alternatives existed. Whether a design defect claim survives FIFRA preemption is the single most important unresolved question after the ruling. The argument for survival: the Supreme Court’s ruling appears to target labeling requirements specifically, and a design defect claim does not require a different label — it requires a different product. The argument against: courts may read the preemption broadly to cover any state-law requirement that conflicts with the EPA’s overall safety determination. This will be litigated in the coming months, and the answer may vary by jurisdiction.
Fraudulent concealment. A fraudulent concealment claim argues that the manufacturer knew about the cancer risks and actively hid them from the EPA, the public, or both. The retracted Williams paper is the strongest factual anchor for this theory — if Monsanto knew the safety data was compromised and submitted it to the EPA without disclosing the problems, that is concealment. Fraud claims are generally not preempted by FIFRA’s labeling provisions because they challenge the manufacturer’s own conduct — its honesty and disclosure to regulators — not the adequacy of the approved label. The Supreme Court has held in other contexts that fraud-on-the-agency claims can survive preemption when they target the manufacturer’s duty to provide truthful information to the regulator. Whether that principle extends to FIFRA and Roundup is unresolved, but it is one of the stronger surviving theories.
Negligent testing and research misconduct. A negligent testing claim argues that the manufacturer failed to conduct adequate, independent safety testing and relied on scientifically compromised research. The retraction of the Williams paper for research misconduct is the evidence. Like fraud, this theory targets the manufacturer’s research practices, not the label. It asks whether a reasonable manufacturer would have conducted more rigorous testing or would have flagged the problems with its existing data. This theory may survive preemption if the court limits the ruling to labeling claims.
Consumer protection and unfair trade practices. Some states have consumer protection statutes that prohibit deceptive marketing and trade practices. If Bayer marketed Roundup as safe while knowing its safety data was compromised, a consumer protection claim — distinct from a failure-to-warn tort claim — may provide a separate path. These claims vary widely by state and depend on the specific statute’s elements and remedies.
Strict product liability (non-warning theories). A strict liability claim that the product was unreasonably dangerous when placed in the stream of commerce — independent of the warning theory — may survive if the preemption ruling is limited to labeling. The viability depends entirely on how broadly the courts interpret the Supreme Court’s preemption holding.
Here is the honest summary: the ruling has dramatically narrowed the field. Failure-to-warn — the strongest, most common theory — is likely gone. What remains are theories that attack the manufacturer’s own conduct rather than the label, and whether those theories survive will be litigated case by case, court by court, in the months and years ahead. No attorney should accept a new Roundup case at pre-ruling valuations without first conducting a theory-specific preemption analysis. And no reader should assume their case is viable — or dead — until that analysis is done.
Bayer and Monsanto: The Corporate Structure Behind the Product
Monsanto developed and commercialized glyphosate beginning in the 1970s. Roundup became one of the most widely used herbicides in the world, applied to more than 300 million acres of U.S. farmland and sold in home-improvement stores to anyone who wanted to kill weeds in their driveway. For decades, Monsanto controlled the product, the research, the regulatory submissions, and the marketing.
In 2018, Bayer AG — a German multinational pharmaceutical and life-sciences conglomerate — acquired Monsanto for approximately $63 billion. Bayer assumed Monsanto’s litigation liabilities, including the growing wave of Roundup cancer lawsuits. At the time of the acquisition, Bayer characterized the litigation risk as manageable. It was not. The pre-ruling landscape produced significant plaintiff verdicts and settlements, and Bayer reportedly committed billions to settlement infrastructure. The Supreme Court’s ruling has now shifted the leverage decisively in Bayer’s favor — which is exactly what Bayer’s own statement acknowledged when it said the decision “should help significantly contain the Roundup litigation.”
The corporate structure matters for your case because naming the right defendant is the first step in any product liability action. Monsanto Company — now a wholly-owned subsidiary of Bayer AG — designed, manufactured, and sold Roundup for decades before the acquisition. Bayer AG, as the corporate parent that assumed those liabilities, is the deep-pocket defendant with global assets. But depending on the jurisdiction, the specific product version, and the date of exposure, the correct named defendant may be Monsanto Company, Bayer Corporation, Bayer AG, or a combination. Identifying the right entity — and the right insurance coverage behind it — is foundational work that must be done correctly at the outset.
Bayer is what we call a balance-sheet defendant. Unlike a trucking company whose recovery is limited by an insurance policy, Bayer’s exposure is limited only by the strength of the legal theory and the proof behind it. Before the Supreme Court’s ruling, that meant plaintiff verdicts could reach into the tens of millions. After the ruling, it means the ceiling is dramatically lower — but the resources to pay a surviving claim are substantial. The question is not whether Bayer can pay. The question is whether your legal theory gets you to the point where they must.
Missouri’s Legal Framework — and How the Federal Ruling Overrides It
The underlying verdict the Supreme Court overturned came from a Missouri state court. Missouri has been a prominent venue for Roundup litigation, and for good reason. Missouri is historically a plaintiff-friendly jurisdiction in mass tort actions. It has no broad statutory cap on non-economic damages in product liability cases — meaning a jury that finds for the plaintiff can award the full measure of pain and suffering, emotional distress, and loss of quality of life without a statutory ceiling cutting the number down. Missouri courts have allowed expert testimony on glyphosate causation, and Missouri juries have produced significant plaintiff verdicts in Roundup litigation.
Missouri’s personal injury statute of limitations is five years — one of the longest in the United States. For wrongful death, the deadline is three years. For toxic tort cases involving latent diseases like cancer, Missouri applies a discovery rule: the clock starts when the plaintiff knew or should have known of the injury and its cause, not when the exposure occurred. This means a farmer diagnosed with non-Hodgkin’s lymphoma in 2024 who only learned of the potential Roundup connection in 2025 may still be within the filing window even if the exposure began in the 1990s.
But here is the critical point: the Supreme Court’s federal preemption ruling overrides Missouri’s state tort law. Missouri’s plaintiff-friendly venue, its absence of damage caps, its willingness to admit causation experts — none of that matters if the legal theory itself is preempted. A Missouri jury can award whatever it wants, but if the Supreme Court says the claim cannot be brought in the first place, the jury never convenes. That is what the 7-2 ruling does. It does not change Missouri’s damages rules. It removes the most common legal theory from the courtroom entirely, regardless of how favorable the venue might otherwise be.
For Missouri plaintiffs, the practical effect is this: the five-year statute of limitations and the lack of damage caps are still advantages, but only for claims that survive preemption. If your attorney identifies a viable design defect, fraud, or negligent-testing theory, Missouri remains a favorable place to pursue it. If the only theory available is failure-to-warn, the federal preemption ruling likely bars the claim no matter how strong the facts.
Your own share of fault can also affect your recovery. Missouri applies a comparative-fault rule that reduces your recovery by your percentage of responsibility, and at a certain threshold can bar recovery entirely. The defense will argue that you used Roundup without reading the label, without wearing protective equipment, or in ways the label did not intend — all to pin percentage points on you and reduce what they owe. Every percentage point is money, which is exactly why the defense works so hard to assign fault to the person who got cancer.
What Your Case May Be Worth After the Supreme Court’s Ruling
We are going to give you the honest range, and we are going to explain why it is what it is.
Before the Supreme Court’s ruling, comparable Roundup non-Hodgkin’s lymphoma cases produced results ranging from modest five-figure settlements to multi-million-dollar verdicts. Bayer reportedly committed billions to settlement infrastructure to resolve claims on a grid that weighed exposure duration, diagnosis subtype, treatment intensity, age, and economic loss. Pre-ruling, a strong case with heavy occupational exposure, a clear NHL diagnosis, aggressive treatment, and significant economic loss could reasonably be valued in the seven figures. A weaker case with incidental residential exposure and a common NHL subtype might resolve in the low six figures or below.
After the ruling, the landscape has changed dramatically. The failure-to-warn theory — the engine that drove the largest verdicts and settlements — is likely preempted. What remains are the surviving theories, and their value is uncertain.
The realistic range for new claims on surviving theories only: $0 to $500,000–$2,000,000. The low end ($0) reflects the possibility that the preemption ruling extends to all strict liability theories, not just failure-to-warn — in which case new claims may be entirely barred. The high end ($500,000–$2,000,000) reflects a surviving design defect or fraud claim with strong facts, significant exposure, a serious NHL diagnosis, and substantial economic loss. Cases with wrongful death components may carry modestly higher values if the applicable state’s survival statute permits recovery on non-warning theories.
These numbers are not predictions. They are the framework an honest attorney uses to evaluate a claim after the ruling has reshaped the landscape. The actual value of any specific case depends on the theory that survives, the strength of the evidence, the jurisdiction, the defendant’s litigation posture, and the individual plaintiff’s damages. No attorney should quote you a specific dollar figure without first conducting a theory-specific preemption analysis and a full damages evaluation.
What we can tell you is what the damages picture looks like when a claim does survive. Economic damages include past and future medical expenses — chemotherapy, immunotherapy, radiation, stem cell transplantation, ongoing surveillance — which can exceed hundreds of thousands of dollars. Lost wages and diminished earning capacity are particularly significant for agricultural workers whose physical labor may never return to pre-diagnosis levels. Non-economic damages — physical pain, emotional distress, loss of quality of life, the psychological burden of a cancer diagnosis — are recoverable in Missouri without a broad statutory cap on product liability claims. Punitive damages remain theoretically available if a surviving claim includes a fraud or concealment theory supported by the retracted Williams paper and internal corporate documents.
The honest bottom line: the ruling has depressed the value of new Roundup claims significantly. Firms that accept these cases at pre-ruling valuations are not doing you a favor — they are setting expectations that the law may not support. What you need is an attorney who will evaluate your specific facts against the surviving theories, give you an honest assessment of what your case is worth in the post-ruling landscape, and tell you plainly whether the path is worth pursuing.
The Evidence You Must Preserve — and How Fast It Disappears
Every Roundup cancer case lives or dies on evidence. After the Supreme Court’s ruling, the evidence matters even more — because the surviving theories (design defect, fraud, negligent testing) require more specific, more documentary proof than the failure-to-warn theory did. Here is what exists, who holds it, and how fast it can legally disappear.
Medical records. Your non-Hodgkin’s lymphoma diagnosis, treatment history, pathology reports, and oncologist’s causation opinion are the foundation of your case. The pathology report confirms the specific NHL subtype — which matters because the scientific literature links certain subtypes more strongly to glyphosate exposure than others. Your treatment records document the chemotherapy cycles, the immunotherapy doses, the radiation sessions, the hospital stays, and the surveillance scans. These records establish your injury, its severity, and its cost. They are retained indefinitely by treatment providers, but you should collect them immediately — not because they will be destroyed, but because your oncologist’s availability for expert testimony degrades over time, and because the medical record is the first thing any attorney needs to evaluate your case.
Exposure documentation. Employment records, agricultural use logs, purchase receipts, and application records that document the duration, frequency, and intensity of your Roundup exposure. This is the evidence that separates an occupational exposure case (a farmer who sprayed Roundup daily for twenty years) from an incidental exposure case (a homeowner who used it once a season on driveway weeds). The dose-response relationship is critical to specific causation, and the defense will fight hard to minimize your exposure history. Farm and business records may be discarded per tax-record retention cycles — typically seven years — which means older purchase receipts and application logs may already be lost. Collect what survives from family members, former employers, and personal records immediately.
Product containers, labels, and purchase documentation. The specific Roundup formulation you used, the label version at the time of exposure, and proof of purchase. This matters for product identification — proving you used Roundup specifically, not a generic glyphosate product — and for the preemption analysis, because the label version determines which EPA labeling determination applies. Product containers degrade or are discarded. Receipts fade. If you still have any Roundup containers, labels, or purchase documentation, preserve them now. Photograph them. Do not assume you will remember the details years from now.
Internal Monsanto and Bayer corporate documents. Emails, research protocols, safety analyses, internal communications regarding the Williams et al. paper, and communications about the IARC classification and the company’s response to it. These documents support fraud, concealment, and negligent-testing theories — the theories most likely to survive preemption. The article confirms that litigation surfaced the retracted paper’s misconduct, which means discoverable internal knowledge exists. But these documents are subject to corporate document-retention policies, and aggressive destruction schedules may apply — particularly as Bayer winds down its settlement infrastructure. An urgent spoliation demand — a formal letter ordering the company to preserve all relevant documents — is needed for any surviving claim. This is something that should happen the day an attorney is retained, not months later.
EPA registration files and administrative record. The regulatory framework and timeline for glyphosate’s registration, labeling correspondence, and the administrative record the EPA relied upon. This may reveal whether the EPA was aware of concerns about the Williams paper’s integrity before its retraction. Federal records are retained, but FOIA requests face multi-month backlogs. File immediately if any claims survive preemption analysis.
The fastest-dying evidence — the records most likely to vanish before you act — is your personal exposure documentation and any remaining product containers. The corporate documents are at risk too, but a preservation letter from an attorney can freeze them. The medical records will be there. What may not be there is the proof of how much Roundup you used, for how long, and in what concentration — and that proof is what makes a surviving theory viable.
The Defense Playbook: What Bayer’s Lawyers Will Do Next
Bayer’s legal team is sophisticated, well-resourced, and now operating from a position of strength. The Supreme Court’s ruling is their primary weapon, but it is not their only one. Here are the plays you should expect, and the counter to each.
Play 1: The preemption motion to dismiss. Bayer’s first move in any new Roundup case will be a motion to dismiss based on the Supreme Court’s preemption ruling. They will argue that every state-law claim — not just failure-to-warn — is preempted by FIFRA because the EPA’s overall safety determination forecloses any state tort claim that would require a different regulatory outcome. Counter: The preemption ruling appears to target labeling requirements specifically. Claims that challenge the manufacturer’s own conduct — fraud, concealment, negligent testing — do not demand a different label and may not be preempted. The motion must be met with a theory-specific legal brief that distinguishes preempted from non-preempted claims.
Play 2: The “EPA said it’s safe” defense. Bayer will lean heavily on the EPA’s determination that glyphosate is “not likely to be carcinogenic to humans.” They will argue that the federal regulator studied the product and found it safe, and that a jury should not second-guess the EPA. Counter: The EPA’s determination was based, in part, on the now-retracted Williams et al. paper — a study pulled from the scientific record for research misconduct. A regulatory determination built on compromised data has diminished scientific authority, even if it remains legally controlling for preemption purposes. For surviving theories, the integrity of the regulatory record is itself the issue.
Play 3: The statute of limitations defense. Bayer will argue that the clock on your claim started running long ago — when you were first exposed, when you first heard about a possible Roundup-cancer link, or when the IARC classification was published in 2015 — and that the deadline has passed. Counter: The discovery rule. For latent diseases like cancer, the statute of limitations in most states starts when you knew or should have known of your injury and its cause. If you were diagnosed with NHL in 2023 and only learned of the Roundup connection in 2025, the clock may have started on the diagnosis date, not the exposure date. Missouri’s five-year personal injury statute — one of the longest in the country — provides a generous window even from the discovery date. But this is a state-specific question that must be analyzed by an attorney familiar with Missouri’s accrual rules.
Play 4: The general causation challenge. Bayer will challenge whether glyphosate can cause non-Hodgkin’s lymphoma at all — attacking the IARC classification, the epidemiological studies, and the plaintiff’s expert witnesses under the Daubert standard. Counter: The IARC classification stands. It was based on peer-reviewed literature, animal studies, and epidemiological evidence. Plaintiff experts in oncology, toxicology, and epidemiology must be prepared to address both general causation and the specific confounders the defense will raise — family history, other chemical exposures, age, immune status — while also confronting the EPA’s contrary position directly rather than allowing the defense to frame it as definitive.
Play 5: The specific causation challenge. Even if general causation is established, Bayer will argue that your specific NHL was caused by something other than Roundup — genetic factors, other chemical exposures, viral infections, age, or pure chance. Counter: A well-documented exposure history, a dose reconstruction by a qualified expert, and an oncologist’s causation opinion that ties your specific NHL subtype to your specific exposure profile. The medical literature links certain NHL subtypes more strongly to glyphosate than others, and your pathology report identifies your subtype.
Play 6: Settlement pressure at depressed values. For existing pending claims, Bayer may use the ruling to push settlement offers at a fraction of pre-ruling values — betting that plaintiffs will accept a reduced recovery rather than risk dismissal on preemption grounds. Counter: An honest evaluation of the surviving theories, the strength of the evidence, and the litigation risk. For some plaintiffs, a depressed settlement may be the rational choice. For others, particularly those with strong fraud or concealment facts, the surviving theories may support a better outcome than Bayer’s post-ruling offer. The decision should be made with eyes open, not under pressure.
Your First Steps: What to Do If You Were Exposed and Diagnosed
If you used Roundup and were later diagnosed with non-Hodgkin’s lymphoma — or if someone you love was exposed and has since passed away — here is what you should do, in order, starting now.
First, gather your medical records. Request your complete medical file from every treating physician, hospital, and cancer center. You want the pathology report that confirms your NHL subtype, the treatment records that document every chemotherapy cycle and hospital stay, the imaging reports that show the disease’s progression, and the oncologist’s notes that discuss potential causes. These records belong to you. Request them in writing. Keep copies.
Second, document your exposure history. Write down everything you can remember about your Roundup use. When did you start using it? How often did you use it — daily, weekly, seasonally? What form did you use — concentrate, ready-to-use, professional-grade? Did you mix it, spray it, or apply it by hand? Did you wear protective equipment? Where did you use it — on a farm, in a nursery, at a golf course, on railroad tracks, around your home? Were you exposed to it at work, and if so, what was your job title and employer? Ask family members and former coworkers what they remember. Old purchase receipts, farm records, employment records, and tax filings may help establish the duration and intensity of exposure.
Third, preserve any product containers, labels, or purchase documentation. If you still have Roundup containers — even empty ones — do not discard them. Photograph the labels. The specific formulation and the label version at the time of your exposure matter for both product identification and preemption analysis. If you have purchase receipts or order records, preserve those too. Receipts fade; photograph them now.
Fourth, do not sign anything from Bayer, Monsanto, or their representatives. If you receive a letter, a phone call, or a visit from anyone representing the manufacturer or its claims administrators, do not provide a recorded statement, do not sign a release, and do not accept a quick check. The Supreme Court’s ruling has given the defense leverage, and they will use that leverage to resolve claims cheaply. Anything you sign now may waive rights you do not yet know you have. Talk to an attorney first.
Fifth, talk to an attorney who understands toxic tort law and the preemption ruling. This is not the time for a generalist. The Supreme Court’s ruling has made the legal landscape complex enough that only an attorney who understands FIFRA preemption, the surviving tort theories, and the specific science of glyphosate-NHL causation can give you an honest evaluation of whether your case is worth pursuing. The consultation should be free. The attorney should tell you plainly whether your facts fit a surviving theory or whether the ruling has likely closed the door. And the attorney should not accept your case at pre-ruling valuations — the landscape has changed, and your expectations should change with it.
Frequently Asked Questions
Can I still sue Bayer after the Supreme Court ruling?
The answer depends on your specific facts and which legal theory your case fits. The Supreme Court’s 7-2 ruling likely preempts state-law failure-to-warn claims — the argument that Bayer should have added a cancer warning to the Roundup label. But other theories — design defect, fraudulent concealment, negligent testing, consumer protection — may survive if they challenge the manufacturer’s own conduct rather than the label. Whether your case fits a surviving theory requires a theory-specific preemption analysis by a qualified attorney. The honest answer is: maybe, but the path is significantly harder and narrower than it was before June 25, 2026. A free consultation with an attorney who understands toxic tort law and the preemption ruling is the only way to know for certain.
What is non-Hodgkin’s lymphoma and how is it linked to Roundup?
Non-Hodgkin’s lymphoma is a cancer of the lymphatic system that affects lymphocytes — white blood cells that help the body fight infection. It can cause swollen lymph nodes, fatigue, unexplained weight loss, night sweats, and fever. The link to Roundup runs through glyphosate, the product’s active ingredient. In 2015, the International Agency for Research on Cancer — the WHO’s specialized cancer agency — classified glyphosate as a “probable human carcinogen” based on peer-reviewed epidemiological studies, animal toxicology data, and mechanistic evidence. The EPA disagrees, maintaining glyphosate is not likely to be carcinogenic — but one of the key studies the EPA relied upon was retracted for research misconduct. The scientific debate is ongoing; the legal door has narrowed.
How long do I have to file a Roundup cancer lawsuit in Missouri?
Missouri’s personal injury statute of limitations is five years — one of the longest in the United States. For wrongful death claims, the deadline is three years. For toxic tort cases involving latent diseases like cancer, Missouri applies a discovery rule: the clock generally starts when you knew or should have known of your injury and its cause, not when the exposure occurred. This means that if you were diagnosed with NHL years after your Roundup use ended, the five-year clock may have started on the date of diagnosis or the date you learned of the potential Roundup connection — not the date you last sprayed the product. But statute-of-limitations rules are state-specific and can be affected by the Supreme Court’s ruling in ways that are not yet fully resolved. An attorney must confirm the deadline for your specific situation.
What evidence do I need to prove my Roundup exposure caused my cancer?
You need three categories of evidence. First, medical records documenting your NHL diagnosis — including the pathology report that identifies your specific subtype, treatment records, and an oncologist’s opinion on causation. Second, exposure documentation — employment records, agricultural use logs, purchase receipts, and any other records that show how long, how often, and in what quantities you used Roundup. Third, product identification — containers, labels, or purchase records that prove you used Roundup specifically, not a generic glyphosate product. The exposure history is often the hardest piece to reconstruct because old records may have been discarded. Start gathering what you can find immediately.
What did the Supreme Court actually decide in the Roundup case?
The Supreme Court ruled 7-2 to overturn a Missouri jury’s verdict for a plaintiff who claimed more than two decades of Roundup exposure caused his non-Hodgkin’s lymphoma. The ruling appears to hold that FIFRA — the federal pesticide-labeling law — preempts state-law failure-to-warn claims when the EPA approved the product label without requiring a cancer warning. In plain language: because the federal government decided Roundup’s label did not need a cancer warning, state courts cannot use tort law to impose a different warning requirement. The ruling is expected to block thousands of similar failure-to-warn lawsuits across the country. It does not eliminate every legal theory — claims that challenge the manufacturer’s own conduct, rather than the label, may survive — but it removes the most common and most powerful theory from the courtroom.
Is glyphosate still safe to use?
The safety of glyphosate is the subject of an active scientific dispute. The International Agency for Research on Cancer classifies it as a “probable human carcinogen” based on peer-reviewed studies. The EPA maintains it is “not likely to be carcinogenic to humans” when used according to label directions. One of the key studies the EPA relied upon — the Williams et al. paper — was retracted for research misconduct. The Supreme Court’s ruling did not resolve the scientific question — it resolved the legal question of whether state tort law can impose warning requirements that differ from the EPA’s federal labeling determination. The science is unresolved; the legal door has narrowed. If you are currently using Roundup, the decision about whether to continue is yours to make with the best information available.
What if my loved one died from non-Hodgkin’s lymphoma after using Roundup?
If your family member was exposed to Roundup and later died from non-Hodgkin’s lymphoma, a wrongful death claim may provide a path to compensation — but only if a viable underlying theory of liability survives the Supreme Court’s preemption ruling. Missouri’s wrongful death statute allows certain family members — typically spouses, children, and parents — to recover for the loss of their loved one’s financial support, companionship, and guidance. The wrongful death deadline in Missouri is three years from the date of death. But the survival of the claim depends on whether a non-warning theory — design defect, fraud, negligent testing — can be established. If your loved one’s case would have been a strong failure-to-warn claim before the ruling, the question now is whether the same facts support a surviving theory. An attorney who understands the preemption ruling can evaluate this.
How much is a Roundup cancer case worth after the Supreme Court’s ruling?
The ruling has dramatically depressed the value of new Roundup cancer claims. The realistic range for surviving theories is approximately $0 to $500,000–$2,000,000, compared to pre-ruling values that could reach into the millions. The low end ($0) reflects the possibility that the preemption ruling extends to all strict liability theories, not just failure-to-warn. The high end ($500,000–$2,000,000) reflects a surviving design defect or fraud claim with strong facts — heavy occupational exposure, a serious NHL diagnosis requiring aggressive treatment, significant economic loss, and evidence supporting the manufacturer’s knowledge of compromised safety data. Cases with wrongful death components may carry modestly higher values. No attorney should quote you a specific dollar figure without first conducting a theory-specific preemption analysis. Past results depend on the facts of each case and do not guarantee future outcomes.
Should I stop using Roundup if I have been using it for years?
We cannot give you medical advice, and the safety of glyphosate is the subject of an active scientific dispute. What we can tell you is that the International Agency for Research on Cancer — the WHO’s cancer agency — classifies glyphosate as a probable human carcinogen, and that one of the key studies supporting the EPA’s contrary position has been retracted for research misconduct. If you are concerned about your exposure, the safest course is to talk to your doctor, research the available alternatives, and make an informed decision. The legal question of whether you can recover if you develop cancer after continued use is separate from the personal question of whether you want to accept the risk.
Can I join a class action lawsuit against Bayer?
Roundup litigation has been managed primarily through individual cases and a federal Multi-District Litigation (MDL) — a procedural mechanism that centralizes pretrial proceedings before a single judge but preserves each plaintiff’s individual case. As of June 2026, approximately 3,900 actions were pending in the Roundup MDL consolidated in the Northern District of California. The Supreme Court’s ruling will significantly impact these pending cases. Whether you can join the MDL or file an individual case depends on your specific facts, the surviving legal theories, and the jurisdiction. This is a question for an attorney who can evaluate your situation and advise on the best procedural path.
Why Attorney911 — and What the First Call Costs
We are Attorney911 — The Manginello Law Firm, PLLC. We are based in Houston, Texas, and we take toxic tort and product liability cases in Missouri, working with local counsel and pro hac vice admission where required. We do not claim an office in Missouri, and we will not pretend to be something we are not. What we are is a trial firm with 27+ years of experience in courtrooms — including federal court — and a team that understands the intersection of federal regulatory law, product liability doctrine, and the specific science of glyphosate and non-Hodgkin’s lymphoma.
Ralph P. Manginello is our Managing Partner — 27+ years of Texas trial practice, admitted to the U.S. District Court for the Southern District of Texas, a journalist before he was a lawyer, and a competitor who hates losing. He approaches every case the way he approaches a cross-examination: with the facts assembled, the law loaded, and the other side’s playbook already mapped. Ralph has spent his career in courtrooms, including federal court, and he understands how preemption rulings reshape the landscape — and how to find the path that survives when the front door closes.
Lupe Peña is our associate attorney — and before he joined our side of the table, he spent years inside a national insurance-defense firm. He sat in the rooms where adjusters and their software decided how to deny, delay, and devalue claims. He knows claim valuation, IME-doctor selection, surveillance, and delay tactics from the inside. Now he uses that knowledge for injured clients. Lupe is fluent in Spanish and conducts full client consultations in Spanish without an interpreter — because the quality of your legal representation should not depend on the language you pray in.
The call costs nothing. The consultation is free. We work on contingency — 33.33% before trial, 40% if the case goes to trial — which means we do not get paid unless we win your case. If your case is not viable after the Supreme Court’s ruling, we will tell you that honestly rather than take a case we cannot win. If your case fits a surviving theory, we will tell you that too — and we will tell you what it is worth in the post-ruling landscape, not in the pre-ruling landscape that no longer exists.
Call 1-888-ATTY-911 — 1-888-288-9911 — any time, day or night. Our line is staffed 24/7 by live people, not an answering service. Hablamos Español. Or contact us through our website and we will call you back.
The Supreme Court has narrowed the door. It has not closed it. If you used Roundup and developed non-Hodgkin’s lymphoma, the science connecting glyphosate to cancer has not changed — and the manufacturer’s own conduct, including the retracted safety study and what it knew and when, may still provide a path. But that path requires an attorney who understands the ruling, the surviving theories, and the evidence you need to preserve before it disappears.
The day you call is the day the preservation letter goes out. The day you call is the day the evidence starts working for you instead of against you. The day you call is the day you stop facing this alone.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Contacting the firm is free and confidential.